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Progress in the field of axonal regeneration research has been like the process of axonal growth itself: there is
steady progress toward reaching the target, but there are episodes of mistargeting, misguidance along false
routes, and connections that must later be withdrawn. This primer will address issues in the study of axonal
growth after central nervous system injury in an attempt to provide guidance toward the goal of progress in
the field. We address definitions of axonal growth, sprouting and regeneration after injury, and the research
tools to assess growth.Introduction
For decades, it has been recognized that axon regeneration is the
only way to restore function after severe spinal cord injuries (SCI)
that interrupt the long tracts that mediate motor and sensory
function. Indeed, SCI and axon regeneration are so linked in the
minds of scientists and the lay public that enabling regeneration
after SCI is iconic. Achieving axonal regeneration with recovery
of function would truly be an extraordinary achievement.
Despite progress, measured both as a gain in understanding
of the molecular-, cellular-, and systems-level underpinnings of
axonal growth, and in the number of investigators studying the
topic, success has not yet been achieved. Indeed, progress
in the field is nonlinear, with many instances of premature cele-
bration of success, mistargeting, sidesteps, and occasional
episodes of withdrawal. The reasons for this are numerous,
ranging from lack of clarity in use of terminology related to axonal
growth and limitations of experimental methods to a lack of rigor
in interpretation.
This primer aims to provide a framework for the study of axonal
growth after spinal cord injury.We focus on SCI not only because
it is iconic, but also because it exemplifies all of the issues that
plague studies of axon regeneration in any CNS region with
mixed white and gray matter. We begin by addressing the
meaning of different terms used to describe growth after injury,
especially the terms ‘‘regeneration’’ and ‘‘sprouting.’’ Incon-
sistent use of these terms in the scientific literature creates ambi-
guity or frank error in interpreting experimental findings. We then
review several model systems for studying axonal growth after
spinal cord injury, highlighting the advantages and limitations
of several models. Finally, we will discuss the tools available to
study axonal regeneration and how these might best be applied
to reach new levels of insight that will point the way to strategies
for improving outcomes after spinal cord injury.
Distinctions between Types of Axon Growth:
Regeneration and Sprouting
There is enormous inconsistency in the literature in the use of the
terms regeneration and sprouting. In part, this is because theterms are defined differently by individuals studying differing
aspects of axonal regeneration and are even defined differently
by those studying the same aspects of axonal regeneration.
Part of the inconsistent use in the field may reflect uncertainty
about what is really happening anatomically.
What defines axonal regeneration? At the organ replacement
level, regeneration can refer to cellular proliferation to replace
tissue. When applied to axons, regeneration refers to regrowth
of a transected axon, as in the case of a peripheral axon growing
back along the distal stump of a crushed or transected nerve to
reinnervate its normal target (Figure 1C). There are nuances in
the application of this simple term in several circumstances,
based on the features of new axonal growth, including from
where along the length of the axon the growth originates, the
distance over which an axon grows, and whether the growing
axon reaches its normal target. This will be discussed in greater
detail below. Most researchers agree that new growth arising
from the cut end of a transected axon, and extending beyond
the lesion site, represents canonical axon regeneration. As noted
above, this can occur after peripheral nerve injury, and nearly
entirely fails after central injury.
The term ‘‘sprouting’’ has been used in a much more incon-
sistent way. Ramon y Cajal used the term to refer to early growth
from the tip of an injured axon: ‘‘the innervation of the peripheral
stump of cut nerves (occurs) through the growth, across
the scar, of nerve sprouts arising in the central stump.,’’
(Ramon y Cajal, 1928, p. 223).
In the renaissance of regeneration research, Liu and Cham-
bers (1958) and McCouch et al., 1958 used the term ‘‘sprouting’’
in a new way to refer to growth arising from an axon that was not
itself damaged (Figure 1G), specifically growth of the central
projections of intact dorsal root ganglion axons after injury to
adjoining roots. This usage followed on earlier studies of growth
of motor axons following partial denervation of muscle (Causey
and Hoffman, 1955; Edds, 1953; Edds and Small, 1951;
Hoffman, 1952).
Use of the term ‘‘sprouting’’ in this manner continued in
studies of growth after injury in numerous brain structures,Neuron 74, June 7, 2012 ª2012 Elsevier Inc. 777
Figure 1. Regeneration and Sprouting
The left side of the panel illustrates several examples of types of regeneration.
(A) Intact axon.
(B) Transected or crushed axon.
(C) Canonical regenerating axon: new growth occurs from tip of transected
axon leading to reinnervation of its normal target.
(D) Regenerating axon, wherein new growth arises not from tip of transected
axon, but from region of axon close to injury site. In some literature, this is
referred to as ‘‘regenerative sprouting,’’ a term we avoid because it can
generate confusion.
(E) Another example of a regenerating axon, wherein new growth arises from
a transected axon, but from a region of the axon that is remote from the injury
site. This type of growth has been described to arise from CST axons in the
cervical spine cord after thoracic level injuries (Bareyre et al., 2004). This has
also been referred to as ‘‘regenerative sprouting.’’
(F) An example of canonical sprouting: here damage to one pathway induces
compensatory growth of new connections from nearby undamaged axons.
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became clear, however, that different growth phenomena were
occurring, sometimes involving cut axons and sometimes in-
volving axons that were uninjured. Many different terms
were applied loosely, including the term ‘‘plasticity’’ (Raisman,
1969), which is now used in somany ways as to be almost mean-
ingless in an anatomical context.
Moore tried to bring some order to the terminological chaos,
defining two basic phenomena:
‘‘A) In regenerative sprouting, the axons of neurons inner-
vating a structure are severed and the axon distal to the
lesion degenerates. The proximal stumps form growth
cones and regenerate new axons and terminals. B) In
collateral sprouting, part of the innervation to a structure
is severed. The distal axons and terminals degenerate
and collateral sprouts form from remaining, uninjured
axons to reconstitute a terminal plexus.’’
As we would use the terms today, the first definition of Moore
would constitute canonical axon regeneration. The second is
incomplete in that it does not encompass the different growth
phenomena that are now known to occur following an injury.
An example of a form of growth that is not encompassed by
the definitions above arises from the spinal cord injury field.
Following a thoracic spinal cord injury, new axonal branches
extend out from corticospinal axons several spinal segments
above the lesion site; these new axonal branches form contacts
with spinal interneurons (Figure 1D) forming a relay that can
restore input to segments beyond the injury (Bareyre et al.,
2004). New branches can also emerge at much higher levels of
the neuraxis including the brainstem after axons are transected778 Neuron 74, June 7, 2012 ª2012 Elsevier Inc.in the spinal cord (Z’Graggen et al., 2000; Figure 1E). It has not
been established whether such novel connections lead to func-
tional relays as in Figure 1D. The use of the term ‘‘sprouting’’ in
this circumstance contradicts the definition of sprouting as
growth arising from a spared, intact axon. A more descriptive
approach for this phenomenon is cumbersome but clear: ‘‘axon
branching arising from the proximal region of a transected
axon.’’ Such a description will avoid confusion regarding the
terms ‘‘regeneration,’’ ‘‘sprouting,’’ or ‘‘regenerative sprouting’’
to describe new growth arising from a transected axon, well
away fromthe lesion site. It shouldbenoted that theabovestudies
did not show definitively that new branches were from axons
that were transected at a lower level. This seems likely, but it
cannot be excluded that new branches came from descending
axons that terminate above the lesion and were not transected.
Subcategories of sprouting have been defined based on the
distance over which axons grow. For example, in the case of
muscle reinnervation following partial peripheral nerve lesions,
very short distance growth arising from spared axon terminals
in the zone of innervation is referred to as ‘‘terminal sprouting.’’
Reinnervation arising from a spared axon has been called
‘‘collateral sprouting.’’ The latter type of sprouting has been
described following partial denervation at multiple levels of the
neuraxis including the spinal cord (Rosenzweig et al., 2009;
Weidner et al., 2001).
There may be even shorter distance growth in which
a surviving axon in a denervated zone forms new presynaptic
specializations on denervated dendrites. This has been referred
to as ‘‘reactive synaptogenesis,’’ a term that may overlap with
‘‘terminal collateral sprouting.’’
Obviously, the proliferation and inconsistent use of terms
leads to lack of clarity. Clarity is improved by simply describing
the actual anatomical event to the extent that is possible, even
if this is cumbersome.
Axon Regeneration after Spinal Cord Injury
There is general agreement that the greatest hope for recovery of
function after spinal cord injury involves regeneration of the long
tracts that mediate sensory andmotor function. But what consti-
tutes ‘‘axonal regeneration,’’ and what is the minimal evidence
required to make the claim that it has occurred?
We propose that the term axon regeneration should be
reserved for (1) growth of a cut axon and (2) extension into or
beyond a lesion. Regenerating axons can either end abortively
(functionally irrelevant), form ectopic connections (could be
either beneficial or detrimental to function), or form connections
with their normal targets (likely to restore function). Regenerating
axons may either extend through a lesion, through something
that is implanted (peripheral nerve bridge, cellular graft, or bioen-
gineered scaffold), or around the lesion through surviving white
or gray matter. The level of proof for axonal regeneration should
be rigorous, and is discussed in the next section.
After a spinal cord injury, there is essentially no re-growth of
axons beyond the point of the injury. Instead, damaged axons
end in what Ramon y Cajal called ‘‘retraction balls.’’ Recent
evidence suggests that these are not static structures, and that
there are periods of extension and retraction. In any case, the
net result is no extension past the point of the original injury.
Figure 2. Anterograde or Retrograde Labeling to Identify New
Axonal Growth
An example of anterograde axonal labeling to identify new axonal growth and
putative regeneration is shown in (A)–(D) (from Lu et al., 2012). Double retrograde
labeling as a means of demonstrating new axonal growth and putative regener-
ation is shown in panel (E) (fromWolfram Tetzlaff, University of British Columbia).
(A) After T3 complete transection, darkly labeled reticulospinal axons
approach the lesion site from the left (rostral) direction in these 35 mm thick
horizontal sections of the spinal cord. A graft (g) of bonemarrow stromal cells is
present in the lesion site. The border between the host spinal cord and the graft
in the lesion site is indicated by black dashed lines. Darkly labeled axons are
seen penetrating the graft (B), and some of these axons have grown to the
caudal aspect of the graft occupying the lesion site, and beyond this point into
the host spinal cord below the lesion site (C and D). The inset indicates one
plane of the complete transection site by GFAP immunolabeling. Green indi-
cates expression of brain-derived neurotrophic factor (BDNF) and a reporter
gene expressed by a lentiviral vector injected into the spinal cord below the
lesion to attract growing axons; IS indicates vector injections sites.
(B) In the graft adjacent to the rostral host/graft interface, numerous host axons
have penetrated the graft.
(C) At the distal graft (g)/host (h) interface, darkly labeled axons cross from the
graft into the spinal cord below. Dashed lines indicate the border between graft
and host. Note the irregular morphology and trajectories of axons growing
beyond the lesion site. Axons are not in tightly fasciculated bundles typical of
intact axons, but instead exhibit highly varied and branchedmorphologies, are
dispersed from one another, and turn in various directions.
(D) 1.5 mm caudal to the lesion site, darkly labeled axons remain detectable
and continue to exhibit varying trajectories. This continues 4mm caudal to the
lesion.
(E)Rednucleus in thebrainstemof the rat.Ratswere injectedwith the retrograde
tracer Fast Blue at cervical segment 8 to back label intact rubrospinal neurons.
The spinal cord was lesioned at the 4th cervical segment eight days later. After
a delay, injured rats were treated with a sciatic nerve graft in the lesion site and
BDNF infusions. Twomonths later, a second retrograde tracerwasplacedat the
free end of the sciatic nerve segment in the lesion site, and the brainstem was
subsequently examined. Some cells in the red nucleus were single labeled for
Fast Blue (arrowheads), and some were double labeled for Fast Blue and BDA
(visualized with the fluorophore Avidic-CY3). Double-labeled cells represented
neurons that grew axons into the peripheral nerve graft; single-labeled cells
represented neurons that did not grow axons into the lesion site.
Scale bar, (A) 1 mm; (A, inset) 0.8mm; (B) 70 mm; (C) 150 mm; (D) 70 mm;
(E) 3 mm.
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axons to grow to some extent. For example, axons may grow
into a spinal cord lesion site that has been experimentally grafted
with cells that provide a matrix permissive for axonal growth,
such as sciatic nerve grafts, fibroblasts, marrow stromal cells,
neural stem cells, or Schwann cells. Because axons are normally
completely absent from the center of a lesion, some would refer
to axonal growth into the lesion site as ‘‘regeneration.’’ But if the
axons growing into the lesion site arise from host axons neigh-
boring the injury that were not transected, then is this growth
‘‘sprouting,’’ ‘‘regeneration,’’ or ‘‘regenerative sprouting’’? There
is usually no way to answer to this question definitively, so use of
the generic term ‘‘axon growth’’ followed by a description of the
location and origin of the growth may be optimal without overin-
terpreting the findings. If it is shown that axons that grow into
a graft originate from intact axons rather than transected axons,
‘‘axonal growth arising from spared axons’’ is accurate. If axons
that grow into a graft unequivocally originate from transected
axons, this would be bona fide ‘‘regeneration.’’ Regardless of
the source of new growth, whether sprouting or regeneration,
functional improvement is the ultimate goal of translational
work in these model systems. However, imprecise or indiscrim-
inate use of terms poses the risk of misguiding or misrepresent-
ing the findings of an experiment, potentially undermining clear
understanding of basic mechanisms influencing axonal growth
after injury and ultimately retarding progress in the field.
What are the minimal criteria to establish a claim for axon
regeneration? First, it is critical to provide compelling evidence
that the axons that extend past a lesion are not spared. Criteria
for this have been described (Steward et al., 2003) and are
reasonably well accepted by the field. Next, how does one prove
that growth involves ‘‘regeneration’’; that is, that an axon growing
into or beyond a lesion site originated from a transected axon?
Evidence Required for Claims of Axon Regeneration
Regeneration can be proven when all of the axons of a projecting
system are lesioned (i.e., no axons are spared), and growth
of labeled axons from an identified source is observed into or
around the lesion site. Usually, this involves tract tracing to iden-
tify the origin, course, and termination of axons (Figures 2A–2D).
Studies in which pathways are labeled by genetically driven fluo-
rescent markers provide an alternative approach providing that
the identity of the labeled axons can be definitively established,
and it can be confirmed that the lesions completely interrupt the
genetically labeled pathway (more on this below).
Somewhat less satisfying, but still reasonably compelling
evidence of regeneration can be obtained through a combination
of double retrograde tracing. For example, in the case of studies
of regeneration of descending pathways after SCI, a retrograde
tracer is injected before the lesion (Figure 2E) to identify the cells
of origin of a pathway that will subsequently be lesioned. After
the lesion is performed and sufficient time has passed to allow
potential axonal regeneration, a second (different) retrograde
tracer is injected at the site of the original tracer injection. Hypo-
thetically, an axon that has regenerated below a complete lesion
of the system will exhibit labeling of the neuronal somata with
both tracers (Figure 2E). A shortcoming of this approach is that
it is not possible to determine the point of origin of the axons
that grow or the course of the axons past the lesion.Neuron 74, June 7, 2012 ª2012 Elsevier Inc. 779
Figure 3. Spinal Cord Dorsal Column Sensory Regeneration Model
The dorsal columns of the spinal cord contain axons that ascend from the
lumbar region to the nucleus gracilis in themedulla. These axons can be traced
as they ascend the spinal cord by injections of the transganglionic tracer
cholera toxin B subunit (CTB) into the sciatic nerve.
(A) In animals that undergo C3 dorsal column transection lesions, CTB labeled
dorsal column sensory axons approach the lesion site, but few penetrate
a graft of bone marrow stromal cells placed in the lesion site; grafted cells
express the reporter gene GFP (from Lu et al., 2004). Sagittal, 35mm thick
section.
(B) A higher magnification view at the light level shows the approach of axons
to the lesion site (upper right), and rare axons in the graft (graft outlined within
black lines). Arrow indicates a single axon that reaches the rostral graft/host
interface, but does not regenerate beyond the lesion site.
(C) Following combinatorial therapy with a conditioning lesion of the sciatic
nerve, a marrow stromal cell graft in the lesion cavity, and lentiviral NT-3
growth factor delivery rostral to the lesion, numerous axons penetrate the graft
and regenerate beyond it. Rostral aspect of graft is outlined by dashed lines.
Regenerating axons within and beyond the graft are indicated by arrowheads.
(D) At the rostral host-graft interface, numerous CTB-labeled axons regenerate
out of the graft and into host white matter beyond the lesion. Axons exhibit
irregular trajectories, make abrupt turns, and are generally dispersed, features
typical of regenerating axons.
(E) At a distance of 2 mm rostral to the lesion site, regenerating host axons are
present in adult white matter. Arrowheads indicate individual axons. From Alto
et al. (2009) and Blesch et al. (2009).
(F) Lesion completeness in this model can be confirmed by examination of the
medulla. In intact animals, dense reaction product is evident in nucleus gracilis
after injection of CTB into the sciatic nerve. Gr, gracilis; Sol, soleus. Transverse
35mm thick section.
(G) In contrast, the nucleus gracilis is devoid of CTB labeling in animals that
have undergone complete C4 dorsal column lesions.
Scale bar, (A) 250 mm; (B) 500 mm; (C) 1mm; (D and E) 20 mm; (F and G) 200 mm.
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mental lesion completely transects the pathway being studied.
Important evidence in this regard can be obtained by an analysis
of axon distribution at different times postinjury. Long-distance
axon regeneration will take some time, including the time
required for (1) recovery from the axonal injury, (2) molecular
changes required for a shift to a growth mode, and (3) elongation
of the axon. Ramon y Cajal provided estimates of the timing of
growth of regenerating peripheral nerves that sound quite
plausible today: (1) preparation of the dividing phase and growth
of sprouts within the central stump (proximal to the injury;
2–5 days); (2) growth through the scar (velocity of 0.25 mm per
day); elongation within the supportive environment of the periph-
eral stump (2.64 mm/day) (Ramon y Cajal, 1928). Even under
‘‘regeneration enabled’’ circumstances, the rate of elongation
may be slower in the CNS.
Studies of Regeneration in Specific Spinal Systems
A spinal cord injury creates a particularly hostile environment for
regenerating axons. Astrocytes surrounding the lesion become
reactive and extend processes. In most species including
humans, the phagocytosis of degenerating neural tissue leads
to the formation of large cystic cavities. If the lesion is complete,
regenerating axons must grow into and beyond the lesion to
reconnect with their normal targets. If the lesion is incomplete,
some axons may extend along surviving bridges of white or
gray matter. Depending on the lesion model and the axonal
projection under study, new growth can occur into, or around,
the lesion. We will now consider different axonal systems in the
study of spinal cord injury, together with issues in assuring lesion
completeness and establishing that regeneration has occurred.
Dorsal Column Sensory Axons: When performed properly,
lesions of the dorsal spinal cord transect all ascending dorsal
column sensory axons. This represents a model that can un-
equivocally demonstrate central axonal regeneration without
requiring transection of the entire spinal cord (Figure 3). Rats
and mice can readily survive this type of lesion with minimal
challenges to survival. Lesion completeness can be established
by confirming an absence of sensory axon terminals in the
nucleus gracilis, for example by tracing ascending projections
arising from the sciatic nerve (Figures 3F and 3G; Lu et al.,
2004; Taylor et al., 2006). Confirmation of lesion completeness
by examination of the nucleus gracilis assumes that regenerating
axons did not reach the nucleus gracilis, an assumption that is
reasonable unless lesions are placed in close proximity to the
nucleus (e.g., C1 level; Alto et al., 2009; Bonner et al., 2011).
Lesion completeness can be further assessed by injecting
retrograde tracers into the nucleus gracilis after a dorsal column
lesion and observing an absence of tracer in the dorsal root
ganglia. There is a caveat about such negative findings, how-
ever, because absence of evidence is not compelling evidence
of absence. For example, there is always a possibility of tech-
nical failure of retrograde transport.
The dorsal column lesion model is helpful for understanding
mechanisms underlying central axonal regeneration and identi-
fying experimental effects of candidate therapies for enhance-
ment of axonal regeneration. Functional sensory deficits can
be assessed, but to restore sensory function, therapies must
lead to axonal regeneration all the way to the nucleus gracilis.780 Neuron 74, June 7, 2012 ª2012 Elsevier Inc.So far, sensory axon regeneration back to the dorsal column
nuclei has only been seen following lesions at high cervical levels
(Alto et al., 2009; Bonner et al., 2011).
Corticospinal Axons: The study of corticospinal tract (CST)
projections is important in spinal cord injury models, as this
Figure 4. The Corticospinal Tract (CST)
(A and B) Corticospinal axons in a mouse are traced here by making placing
four injections of mini-ruby BDA into the right sensorimotor cortex. CST axons
from the right hemisphere are labeled. In mice, CST axons descend primarily in
two tracts: the dorsal CST, in the ventral part of the dorsal column (dCST), and
the dorsolateral CST (dlCST) in the dorsal part of the lateral column. Note the
absence of labeled axons in the ventral column on the right side; in rats, some
axons are present in this region. Note also the presence of a few labeled axons
in the dorsal column on the right in the same location as the dCST. This
illustrates the fact that there are a small number of axons that descend in the
spinal cord ipsilateral to the cortex of origin. In this case, labeled CST axon
arbors are found mainly in the ventral horn gray matter. The distribution of
axonal arbors depends on whether the injections target mainly the sensory
versus motor divisions of the sensorimotor cortex. Injections that mainly target
the primary motor cortex preferentially label CST axon arbors in the ventral
horn whereas injections that mainly target the sensory cortex preferentially
label CST axon arbors in the dorsal horn.
(C) Schematic illustration of partial transection lesions that are commonly used
for assessing CST regeneration in mice and rats. The red region denotes a
dorsal hemisection; the blue region indicates a ‘‘T’’ lesion, which is intended to
include the ventral CST in rats (modified from Zheng et al., 2006).
(D and E) Corticospinal axons in a rat are traced here by making six injections
ofmini-ruby BDA into the right sensorimotor cortex. Labels are as in (A) and (B).
In this case, labeled axonal arbors are found mainly in the dorsal horn gray
matter.
(F) Higher magnification view of BDA-labeled axons in the ventral column
(vCST). Scale bars = 250 mm.
(G and K) Sprouting of CST axons below a hemisection injury in rhesus
monkeys. (G) The schematic on the left illustrates the organization of theCST in
rhesusmonkeys. Descending CST axons from the left motor cortex are shown.
The main component of CST axons descend in the lateral column, as in
humans. About 87% descend on the side contralateral to the cortex of origin;
11%descend through the lateral column on the ipsilateral side; the ventral CST
contains about 2% of the total number of labeled axons. The schematic on the
right illustrates the lesion model, a hemisection at C7, and the CST axons that
would survive such lesions. The box indicates the CST arbors in the gray
matter that arise from axons decussating across the spinal cord midline.
(H) Density of BDA-labeled CST axon arbors in the gray matter in intact
monkeys (which includes labeled axons from the main tract and the crossing
axons); (I) arbors of surviving crossed CST axons at early time points after
a C7 hemisection; (J) arbors of crossed CST axons traced 8 months after
a hemisection injury, when extensive compensatory sprouting has occurred.
(K) Quantitative assessment of the density of crossed CST axons in the gray
matter in intact monkeys, at short intervals after the injury, and at long post-
injury intervals. By 8 months postlesion, there is a substantial reconstitution of
Neuron
Primermotor projection is critical for human voluntary motor function.
However, because CST axons descend in several different
tracts, it is particularly challenging to distinguish regeneration
from sprouting of spared axons and to detect inadvertently
spared axons.
In species usedmost extensively for experimental studies, cor-
ticospinal axons originate primarily from neurons in layer V in the
sensorimotor cortex. It is important to note, however, that other
cortical areas also contribute, including the dorsomedial frontal
cortex. Most CST axons decussate in the pyramidal decussation
and then descend through the spinal cord in three tracts: a dorsal
tract in the ventral part of the dorsal column (the main tract in
rodents), a dorsolateral tract (the main tract in primates), and
a ventral tract that is sparse in most species and is not detected
in some strains of mice (Figure 4). The dorsal and dorsolateral
CST contain axons from the contralateral cortex whereas axons
in the ventral CST are from the ipsilateral cortex. Our impression,
based on assessment of labeling in hundreds of rats andmice, is
that the parcellation of axons between the twominor tracts varies
even across individuals within the same species.
Regarding the use of rodent models for spinal cord injury
studies in general and CST regeneration in particular, it is note-
worthy that most CST axons in rodents are located in the spinal
cord dorsal white matter; this is a key distinction from humans,
where the main CST descends in the lateral columns.
CST axon collaterals leave the main tract and terminate mainly
on the side contralateral to the cortex of origin. Some CST axons
recross the midline at segmental levels to terminate ipsilaterally
(Figure 4). Recrossing axons are sparse in rats, somewhat
more common in mice, and are prominent in primates. The
extent of recrossing in humans is not known.
Several publications have reported regeneration of CST axons
after spinal cord injury in rodents, but many of these studies
leave doubts. Unless the spinal cord is transected completely,
lesions usually spare axons in one or the other of the component
pathways, so that axons observed below the lesion site could be
due to sprouting from spared axons. Complete transections can
solve this problem, but are difficult to create and are extremely
disabling to the animals. Many early claims of CST regeneration
after complete transection have not stood the test of time and
replication, based on later evidence that axons were actually
spared. Most often, spared axons lie within the most ventral
and lateral aspects of the lesion site. Also, complete transections
create an environment that is an extraordinary barrier because
the two stumps pull apart leaving a fluid filled space that can
be many millimeters in length. Even when filled with a transplant
or a growth-promoting substrate, a large lesion represents a very
challenging barrier for regenerating axons. In our view, no study
to date has convincingly demonstrated regeneration of CST
axons across a complete spinal cord transection site, and this
remains a key goal of spinal cord regeneration research.
Although complete transection, properly done, may be the
‘‘gold standard’’ for demonstrating regeneration, achievingcorticospinal axons below the lesion site, due to sprouting of spared contra-
lateral axons.
(G)–(K) are from Rosenzweig et al. (2010). Scale bar in (I) = 100 mm and applies
to (H)–(J).
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Figure 5. CST Tract Reconstruction
CST axons were anterogradely traced with BDA in a PTEN-deleted mouse that
survived for a total of 12 weeks following a complete spinal cord crush at T8.
The image illustrates BDA-labeled axons in 50 mm thick serial sagittal sections.
Labeled axons in each image were traced in Adobe Photoshop, and the
tracings were stacked and superimposed onto a light micrograph of one
section containing the central canal. Axon segments are rainbow color-coded
according to depth of each of the 8 serial tissue sections, thus color-coding
relative depth in 50 mm increments through 400 mm of tissue. Order of colors is
red, orange, yellow, yellow green, green, cyan, blue, purple. This image is from
the case described in Liu et al. (2010) in which sections were embedded and
sectioned for electron microscopy in order to locate BDA labeled synapses.
(Image courtesy of Rafer Willenberg, UC Irvine.)
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to identify a meaningful therapeutic advance. Indeed, the bar is
even higher than most cases of human spinal cord injury
because human injuries are most often crush injuries due to
vertebral displacement or contusion injuries. There is often at
least some spared rim of white matter even in severe human
injuries.
Because a complete lesion is technically difficult, disabling for
the animal, and creates a substantial barrier to regeneration,
most contemporary studies of CST regeneration use partial
injury models. One commonly used model is a dorsal hemisec-
tion (Figure 4C), which in rats, spares the ventral CST. When
the ventral CST is spared after removal of all dorsal projections,
ventral projections can exhibit remarkable branching and ramifi-
cation that support partial functional improvement (Weidner
et al., 2001).
Contusion injuries created by impactors can completely
destroy the dorsal CST but usually spare both the dorsolateral
and ventral CST, which can be a source of sprouting below the
injury. Given the extent and variability of the contusion lesion, it
is very difficult to determine whether CST axons caudal to the
injury are the result of sprouting from spared axons or regenera-
tion. The former is far more likely.
A ‘‘T lesion’’ has been used in rats (Figure 4C) in an attempt
to eliminate all dorsal, dorsolateral and ventral CST axons
(Liebscher et al., 2005), but these lesions are technically very
challenging and, potentially, of variable accuracy. Also, as typi-
cally performed, the lesions can spare the dorsal part of the
lateral column, potentially sparing axons of the dorsolateral CST.
Lateral hemisections have also been used to examine cortico-
spinal growth after destroying CST axons traveling on one side of
the spinal cord. In rodents, it is difficult to selectively destroy CST
axons on one side because themain component of CST axons in
the dorsal column is adjacent to the midline. Often, the lesions
spare axons near the midline or extend across the midline
to involve the contralateral, ‘‘intact’’ system. Accordingly, the
lateral hemisection model in rodents is vulnerable to uncer-
tainties both with regard to regeneration and sprouting. More-
over, some corticospinal tract axons decussate across the
spinal cord midline; these spinal-decussating axons are sparse
in normal rats, but are present in mice and common in primates
(Rosenzweig et al., 2009). Indeed, following a lateral hemisection
in primates, corticospinal axons that normally decussate across
the spinal cord midline sprout exuberantly and reconstitute up to
50% of axon terminals lost after lateral hemisection, a remark-
able degree of anatomical plasticity (Figures 4G–4I; Rosenzweig
et al., 2010).
Spinal cord ‘‘crush’’ models (even ‘‘complete’’ crush) can
spare tracts of white matter and are difficult to create consis-
tently. Sparing of ventrally located axons is particularly pro-
blematic. Careful histological analyses can address some of
these concerns, with rigorous documentation of lesion extent
and serial tracing of axons across different planes of sampling
(Figure 5). Functional analyses are compromised unless
thorough histological analyses are carried out on every animal
to confirm lesion completeness.
In all of these partial lesion models, strong, supportive evi-
dence can mitigate concerns about sparing. If the axons take782 Neuron 74, June 7, 2012 ª2012 Elsevier Inc.a course that is not seen in uninjured animals, the claim for
regeneration can be persuasive. For example, deletion of the
tumor suppressor gene ‘‘phosphatase and tensin homolog’’
(PTEN) in mice after either dorsal hemisection or severe crush
lesion results in bilateral extension of CST axons below the lesion
that originate from a single hemisphere (Liu et al., 2010). Such
bilateral projections are extremely rare in controls, and their
abundance in PTEN-deleted mice is supportive evidence for
regeneration.
Even when it can be established that axons have regrown past
the lesion, it is usually not possible to conclude with certainty
whether these axons originate from transected axons or from
sprouts of spared CST axons that ordinarily terminate rostral to
the injury. This requires complete reconstruction of the origin
and course of the axons, which in turn requires sparse labeling.
Absence of CST Growth into Grafts and Transplants
Many studies have assessed whether grafts or transplants
can support CST growth. Implanted matrices have included
Schwann cells, astrocytes, neural stem cells, fibroblasts, oligo-
dendrocyte precursor cells, bone marrow stromal cells, or other
substances (Blesch and Tuszynski, 2009). While these matrices
support the growth of other motor systems, including raphespi-
nal, rubrospinal, and reticulospinal projections after injury, it is
noteworthy that none of these matrices support CST axon
growth. The only matrix to date that supports CST growth is
the grafting of fetal spinal cord (Coumans et al., 2001), and
even then, growth is modest. Also, fetal spinal cord grafts are
of limited practical usefulness because the grafted cells exhibit
variable survival and rarely fill the lesion site (Coumans et al.,
2001). A major unmet challenge in the field of spinal cord injury
research remains the identification of a substrate or matrix that
will enable CST axon growth into a cystic lesion site.
Figure 6. Raphe-Spinal Pathways
(A) Retrogradely labeled neurons in the midline raphe and reticular formation
after injections of true blue into the spinal cord of a mouse. Neurons in the
raphe nucleus give rise to serotonergic (5HT) axons that project to the spinal
cord.
(B) Immunofluorescence for 5HT in the thoracic spinal cord. CC = central
canal.
(C) Immunolabeling for 5HT after a ‘‘complete crush’’ injury in mice. The lesion
site is indicated.
Scale bars, 250 mm.
Figure 7. Brainstem Motor Pathways: Rubrospinal, Reticulospinal,
and Vestibulospinal Tracts
(A–C) Retrogradely labeled neurons in the brainstem after injections of true
blue into the spinal cord of a mouse. (A) red nucleus; (B) vestibular nucleus; (C)
locus ceruleus and Barrington’s nucleus.
(D–F) BDA labeled axons after a large injection of BDA into the brainstem of a
mouse. RuST, rubrospinal axons; RST, reticulospinal axons; VST, vestibulo-
spinal axons. Note collaterals extending from the RuST into the gray matter in
(E). Collaterals in (F) are likely from the RST or VST.
Scale bars, 250 mm.
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therapeutic manipulations, other descending systems including
raphespinal, cerulospinal, reticulospinal, rubrospinal, and pro-
priospinal axons are somewhat more responsive (Blesch and
Tuszynski, 2009). These systemsmediate functions (locomotion,
posture, balance, autonomic control) that would be important to
comprehensively improve functional outcomes in people with
SCI (Anderson et al., 2008).
Serotonergic Systems
Serotonergic projections to the spinal cord from the brainstem
raphe nuclei modulate the activity of spinal motor systems,
and preservation or restoration of serotonergic input improves
locomotor function (Courtine et al., 2009; Rossignol and Dubuc,
1994; Thompson et al., 2011). Raphespinal axons arise from
cells in the midline raphe (Figure 6) and travel caudally through
the spinal cord as dispersed bundles of axons neighboring the
central gray matter (Figure 6). Complete lesions of raphespinal
axons require extensive bilateral lesions that extend ventrally
well below the central canal. Accordingly, the most reliable
model for examining regeneration of this system is a complete
spinal cord transection or crush (Figure 6C). While there has
been some question regarding the existence of intrinsic sero-
tonin-containing neurons with the spinal cord that would compli-
cate the assessment of axonal regeneration even below
a complete transection site, routine serotonin immunohisto-
chemistry with an antibody to 5-hydroxytyptamine (5HT) doesnot detect residual neuronal or axonal labeling below a complete
injury (Figure 6C). Although there are few reports of regeneration
after complete lesions (Coumans et al., 2001), the extent of
regeneration reported is modest.
Many previous studies report treatment-related increases in
serotonergic axons below an injury and growth of serotonergic
axons into partial spinal cord lesion sites containing cell grafts
(Lu et al., 2003). Such growth could result either from regenera-
tion of transected axons or sprouting of neighboring axon
terminals that were spared by the lesion. Distinguishing between
these is probably impossible, so ‘‘increase in serotonergic axon
density’’ or ‘‘axon growth into the lesion site’’ is the most appro-
priate phrases for describing these forms of axon growth.
Rubrospinal Axons
Rubrospinal projections are considered to be rudimentary in
humans although this point is not entirely settled (Nathan and
Smith, 1982; ten Donkelaar, 1988). In rodents, rubrospinal axons
arise from the magnocellular division of the red nucleus (Fig-
ure 7A), cross the midline, and project through the dorsal part
of the lateral column of the spinal cord andmodulate motor func-
tion. (Ku¨chler et al., 2002; Morris et al., 2011). Rubrospinal axons
can be labeled by making tracer injections into the brainstem
(Figures 7Dand7E show thepathway after injections in amouse).
The rubrospinal tract can be completely transected by lateral
funicular lesions, which therefore represent an attractive model
system for the study of mechanisms underlying motor axon
regeneration, albeit with the important caveat that the projection
is of limited importance in humans. Rubrospinal axons exhibit
a greater capacity to regenerate than CST axons (Liu et al.,Neuron 74, June 7, 2012 ª2012 Elsevier Inc. 783
Neuron
Primer1999). This system, like others, is also subject to the caveat that
growth into or beyond a lesion site can arise from either sprout-
ing of spared axons or regeneration of transected axons unless
it can be confirmed by complete reconstruction of axons ex-
tending past the lesion that growth originated from an axon
that was unequivocally cut. In the absence of such confirmation,
studies of this system should apply the term ‘‘axonal growth’’ in
subtotal lesion models.
Reticulospinal Axons
Reticulospinal projections are the principal motor pathways
in lower vertebrates that lack a cortex. In limbless animals,
reticulospinal pathways control trunk musculature to mediate
swimming and crawling. In vertebrates with limbs, reticulospinal
pathways activate spinal motor neuron pools involved in a variety
of functions including locomotion and postural maintenance
(Alstermark et al., 1983; Shapovalov and Gurevitch, 1970; ten
Donkelaar et al., 1980; Wilson and Yoshida, 1968).
Several brainstem nuclei give rise to reticulospinal projections,
with the greatest density arising from the pontine gigantocellular
reticular nucleus. Reticulospinal axons can be labeled by inject-
ing anterogradely transported tracers into the brainstem (Fig-
ures 2 and 7), but tracer injections may also label other spinally
projecting brainstem axonal systems, including vestibulospinal,
rubrospinal, cerulospinal, and raphespinal tracts. Axons that
are labeled in the spinal cord as a result of tracer injections
targeting the reticulospinal pathway are widely dispersed in the
spinal cord but are predominantly located in the ventral column
(Figures 7D and 7F). Because descending axons are dispersed,
complete spinal cord transections are the best model to
unequivocally assess whether axons of this system have regen-
erated. Reticulospinal axons grow into cellular matrices placed
within partial spinal cord lesion sites (Blesch and Tuszynski,
2009; Jin et al., 2002), and, as with other systems described
above, this growth may arise either from regeneration of trans-
ected axons or sprouting of neighboring, intact axons. Unless
there is compelling evidence that ingrowing axons arise from
an axon that has definitively been cut, the term ‘‘axon growth’’
should be used when referring to axons that extend into a lesion.
When interventions increase axon number below a lesion,
‘‘increase in reticulospinal axon number’’ is themost appropriate
phrase.
Cerulospinal Axons
Noradrenergic inputs to the spinal cord arise from the locus
ceruleus (Figure 7C) just dorsal to another important nucleus
called Barrington’s nucleus that is a key regulator of bladder
function (Figure 7C). Cerulospinal axons modulate the activity
of intraspinal circuitry including motor systems (White and
Neuman, 1980). These projections travel in dispersed bundles
of axons predominantly in lateral spinal cord white matter and
can be identified by immunolabeling for tyrosine hydroxylase
(TH) or dopamine beta hydroxylase (DBH) (Tuszynski et al.,
1994; Figure 7). The same general issues apply with this system
as for the other pathways in terms of documenting regeneration
and distinguishing regeneration and sprouting.
Propriospinal Axons
Propriospinal neurons project up and down the spinal cord to
coordinate spinal circuitry, including interlimb coordination
(Kostyuk and Vasilenko, 1978; Alstermark et al., 1984; Courtine784 Neuron 74, June 7, 2012 ª2012 Elsevier Inc.et al., 2008). There are no specificmeans of identifying these pro-
jections, as the neuronal somata are located in spinal cord gray
matter and are difficult to selectively target with tracer injections.
Thus, these projections have been difficult to study in the context
of spinal cord injury. By injecting retrograde tracers into the
stumps of sciatic nerve grafts or tubes placed in sites of
complete spinal cord transection it has been shown that intra-
spinal neurons extend axons into permissive matrices placed
in lesion sites (Xu et al., 1997). New advances involving genetic
labeling of defined neuron types hold the potential to make this
population of neurons amenable to experimental study (more
on this below).
Distinguishing New Axonal Growth from Incomplete
Lesions
No discussion of axonal growth after spinal cord injury, whether
resulting from regeneration or sprouting, is complete without
reference to the problem of ‘‘false resurrections.’’ This refers to
the risk of mistaking an unintentionally spared axon for a newly
growing axon. This issue in spinal cord regeneration research
is no less important—or problematic—today than when it was
addressed in detail in 2003 (Steward et al., 2003). Few additional
comments can be added to the original commentary. It remains
vitally important that any description of new axonal growth avoid
this major pitfall, which can divert the field for years in pursuit of
ephemeral notions that ultimately fail the test of replication.
Other Pitfalls
Two other potential sources of error in judging axonal growth
after injury merit discussion. Depending on the type of spinal
cord lesion created, and particularly in the case of compres-
sive/contusive type injuries, the lesion gradually expands over
several weeks into an oval or cigar-shaped cavity extending
along the rostral-caudal spinal cord axis (Gruner et al., 1996).
Thus, what begins as a small lesion can become an enlarged,
elongated lesion. In judging axonal growth into and beyond
this type of lesion, it is critical to define the boundaries of the
expanded lesion so that one does not mistakenly assume axons
have regenerated beyond a lesion when in fact they remain
within a (larger) lesion. Immunostaining for GFAP provides one
way to define lesion margins, and immunostaining for vimentin,
nestin, or NG2 can also be useful (Fitch and Silver, 2008). A
second issue to consider in judging the effect of an experimental
manipulation on axonal growth is the ‘‘dying back’’ phenomenon
(Ramon y Cajal, 1928), wherein lesioned axons typically retract
from the site of injury. Myelinated axons often retract approxi-
mately one myelinated segment to a node of Ranvier proximal
to the lesion site. If an experimental therapy reduces axonal
dieback, then it is possible to mistakenly interpret this as new
axonal growth up to the lesion margin. This error can be avoided
by sampling several time points shortly after the lesion, to
determine whether axonal dieback followed by new growth
has actually occurred.
Summary of Guidelines for Demonstrating Axonal
Regeneration
Evidence to support a claim that an injured axon has regenerated
into or beyond a lesion should ideally include the following:
(1) Use of a model in which regenerated axons can be defin-
itively distinguished from spared axons. Options include
Figure 8. Three Dimensional Imaging of the Unsectioned
Spinal Cord
Using tetrahydrofuran-based methods, the unsectioned adult rat spinal cord
can be ‘‘cleared,’’ supporting visualization of the course of individual, fluo-
rescently labeled axons through a spinal cord lesion site (Ertu¨rk et al., 2012).
This supports tracing the origin and course of individual, lesioned axons.
(A) The whole-mounted spinal cord in a 3D representation, showing axons
labeled in transgenic M mice (Feng et al., 2000) expressing GFP in sparse
neuronal populations (Ertu¨rk et al., 2012).
(B) Reconstruction of a plane of section from the same spinal cord demon-
strating GFP-labeled sensory axons (arrows) approaching and growing within
a lesion site (lesion margins indicated by dashed lines). Rats underwent
peripheral ‘‘conditioning’’ lesions of the sciatic nerve to enhance regeneration.
Caudal is to the right, rostral to the left; the direction of axonal regeneration is
right to left (courtesy of A. Ertu¨rk and F. Bradke).
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have been cut or a partial lesion or crush/compression
models in which individual ‘‘regenerating’’ axons can be
unequivocally traced to their point of origin in the lesioned
tract (either strict serial section reconstruction or analyt-
ical techniques using unsectioned spinal cord) (Ertu¨rk
et al., 2012; Figure 8). Documentation of lesion extent is
critical. A single photomicrograph showing a ‘‘complete’’
lesion in one 40 mm thick section is not evidence of
a complete lesion in the remaining 3, 000 mm of spinal
cord; systematic sampling and documentation of lesion
extent through the full width of the spinal cord should be
provided.
(2) A demonstration that the morphology of putatively grow-
ing axons is consistent with new axonal growth: strictly
linear axons in normal tracts strongly suggest axonsparing, whereas regenerated axons will more likely
exhibit an irregular growth trajectory (Lu et al., 2004).
(3) A time course analysis confirming that axons actively
extend over time starting from the point of injury, extend-
ing into or around a lesion site, then gradually beyond the
lesion over clear serial time points.
(4) Where possible, a confirmation of loss of innervation of
targets. Residual labeling likely represents an incomplete
lesion unless compelling evidence is presented to the
contrary. In complete transection models, the absence
of detectable axons at long distances beyond the lesion
suggests a complete lesion; in dorsal column sensory
axon transection models, sectioning of the medulla
should confirm an absence of axons in the target
(Lu et al., 2004).
(5) A demonstration of an absence of similar labeling in
convincing controls, with adequate numbers of subjects.
Supportive evidence, in addition to the preceding, to support
a claim of regeneration includes the following:
(1) Demonstration that axons are located in ectopic loca-
tions, outside the normal topography of axon distribution
for the system under study, reflecting new growth.
(2) If axons are growing through an implant of some type
placed in the lesion site, visualizing axon growth not
only from the most ventral, dorsal, or lateral aspects of
the lesion site, where spared axons are most likely to be
present, but through the central regions of the implant.
Finally, independent replication of a reported experimental
effect lends confidence. One clear example of successful repli-
cation in spinal cord injury research is the growth-enhancing
effect of conditioning lesions of the sciatic nerve on centrally
projecting sensory axons (Bisby and Pollock, 1983; McQuarrie
et al., 1977; Neumann and Woolf, 1999; Oudega et al., 1994).
Moreover, efficacy in different models of SCI further confirms
the biological validity of a presumed mechanism related to
regeneration.
SCI versus Other Models for Studies of Axonal
Regeneration
We have focused on spinal cord injury because it exemplifies the
problems that arise in studies of axon regeneration in most areas
of the CNS. There is an extensive literature on axon regeneration
in the olfactory nerve and optic nerve, but these CNS structures
differ in important respects from the spinal cord or other CNS
areas. The olfactory nerve is a special case because olfactory
receptor neurons undergo continuous turnover, so there is
naturally occurring axon growth in the nerve. This may reflect
the fact that the olfactory nerve contains a special type of glial
cell, olfactory ensheathing glia (OEG), that either support or are
at least permissive for olfactory axon growth.
The optic nerve is also a CNS structure; it contains the central
processes of retinal ganglion cells, which are axonal in nature
and are indistinguishable anatomically from other CNS axons.
The glial environment of the optic nerve consists of oligodendro-
cytes and astrocytes, replicating inhibitory features at sites of
injury consisting of astrocytic ‘‘scar’’ formation and the presenceNeuron 74, June 7, 2012 ª2012 Elsevier Inc. 785
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others; (Benson et al., 2005; Bray et al., 1991; Cao et al., 2010;
Giger et al., 2010; Keirstead et al., 1989; Lo¨w et al., 2008;
Schwab et al., 2006)). Like other central axons, optic nerve axons
fail to regenerate beyond this inhibitory milieu (Benowitz and Yin,
2008; Bray et al., 1991; Park et al., 2008). The optic nerve differs
from other CNS areas in several respects, however. First, it is
a pure axonal tract (no gray matter). Second, in distinction to
most spinal axons, the vast majority (>99%) of retinal ganglion
cells die after optic nerve transection, a far greater proportion
than the number of degenerating neuronal cell bodies that give
rise to axons traversing a spinal cord lesion site. This raises the
possibility that a unique biological feature of a subset of surviving
retinal ganglion axons is the actual subject of study. The
simplicity of the optic projection to thalamic and collicular targets
is a virtue: the nerve consists essentially of a single projection to
few targets. If an optic nerve lesion is complete, then there is little
question that regeneration has occurred. However, its simplicity
is also a drawback: the optic nerve model poorly replicates the
diverse and complex nature of a spinal cord injury, which
by virtue of containing both gray and white matter results in
hemorrhagic necrosis, extensive inflammation, and secondary
cell death and cavitation. Moreover, the complex circuitry of
the spinal cord presents a diversity of inappropriate targets
through which growing axons must hypothetically navigate
before restoring useful function. Thus, the primary strength of
the optic nerve model may lie in understanding fundamental
mechanisms underlying axonal degeneration and regeneration,
leading to the identification of targets that can then be tested
in models of SCI (Kurimoto et al., 2010; Park et al., 2008). The
model is discussed in more detail in other reviews (Benowitz
and Yin, 2008; Maclaren and Taylor, 1997).
Peripheral Nerve Injury
Studies of peripheral nerve injury have been invaluable in
identifying neural mechanisms that underlie successful regener-
ation (Griffin et al., 2010; Longo et al., 1984; Ma et al., 2011;
Ramon y Cajal, 1928); peripheral nerve injury models continue
to yield important findings in the field (Ma et al., 2011; Mantuano
et al., 2011). The difference in perception between investigators
studying central versus peripheral axonal regeneration can be
amusing, as peripheral nerve investigators highlight the incom-
pleteness and limitations in axonal regeneration after injury,
whereas spinal cord investigators relish the day that growth
of central axons will begin to approach the intrinsic capabilities
of peripherally injured axons. As noted early in this monograph,
there is also often a gulf in the use of the terms ‘‘growth,’’
‘‘sprouting,’’ and ‘‘regeneration’’ as applied in the peripheral
nerve literature and the CNS. A review of peripheral nerve
models is beyond the scope of this Primer and interested readers
are referred to recent reviews (Griffin et al., 2010; Zochodne,
2012).
Why Are Controls Sometimes Inadequate?
Comparison of an experimental treatment group to an untreated
or inactive-drug control group would seemingly compensate for
several potential errors addressed in preceding sections. Yet this
is often not the case. Several classes of errors can account for
mistaken findings despite the use of control groups.786 Neuron 74, June 7, 2012 ª2012 Elsevier Inc.A common error is underpowering of studies. This topic has
been addressed in detail in a recent monograph (Scott et al.,
2008). Conceptually, inadequate numbers of study subjects
would most commonly lead to the mistaken conclusion that
a treatment has no effect (a type II statistical error), when in
fact greater numbers of subjects are required to demonstrate
the effect of a smaller yet biologically significant effect. The
problem is that underpowered studies with negative results are
not generally published. Consequently, underpowered studies
that yield statistically significant results (a type I statistical error)
may be overrepresented in the literature. Indeed, there have
been several reports in the field of spinal cord injury research
where early suggestions of treatment effects evaporate when
larger numbers of subjects are examined. The problem of prefer-
ential publication of studies with type I statistical errors has been
called the ‘‘file drawer problem’’ (Kennedy, 2004): journals are
the likely repository of the 5% of the studies with Type I errors
while file drawers contain the 95% of the studies in which differ-
ences do not reach statistical significance.
This and other problems of reproducibility have been high-
lighted by the FORE-SCI Project sponsored by the National Insti-
tutes of Neurological Disorders and Stroke. The Program funded
contracts that supported replication of promising reports related
to neuroprotection or regeneration. Of 11 published replications,
only one (a study involving a neuroprotective strategy) has fully
confirmed the findings in the original report (for a review, see
Steward et al., 2012). Mistaken conclusions retard progress in
the field and drain resources; greater efforts are required to avoid
these miscues. Efforts by experimentalists to gain training in
models of spinal cord injury, together with the use of proper con-
trols, blinded treatments and assessments, and true observer
objectivity, will reduce, but not always eliminate, the risk of
errors.
An adequate sample size to determine the effect of an
experimental treatment varies by the potential effect size of the
treatment, and the variability of the measures used to assess
the outcomes. For example, when using a complete spinal
cord transection model, control groups exhibit no detectable
supraspinal axons below the lesion. If a treatment actually
causes regeneration, relatively few animals (less than 6 per
group) would provide reliable anatomical outcome data because
all values in the control group would be ‘‘0.’’ In partial lesion
models, it is more difficult to achieve consistency, so variability
in outcomes usually increases, and greater sample sizes are
needed.
When function is the outcome measure, there can be con-
siderable variability arising from several sources. First, behav-
ioral performance is influenced by multiple factors other than
the anatomical substrate (motivation, concurrent illness, various
medications, etc.). Second, functional outcome is related to final
lesion size, and many physiological factors contribute to final
lesion volume, only some of which are under experimental
control (for example, extent of hemorrhage). Accordingly, func-
tional outcome studies may require dozens of animals per group
to reach reliable conclusions in partial lesion models. Rarely are
studies of such size performed, however. Moreover, studies with
a large ‘‘n’’ can only be performed by staging over time, which
creates other ambiguities.
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mental outcome is the use of controls from previous studies in
a new set of experiments (historical controls) or combining of
animals into single groups from experiments conducted at
different time points (Sharp et al., 2012). Some of the variables
that drift over time include techniques of surgery, postoperative
care, data collection (especially in functional assessment), and
even the routine handling by vivarium staff. All of these variables
are directly related to personnel, and even if the same people are
involved, skill level changes over time. Variables unrelated to
personnel include time of year and genetic constituency of the
study subjects (particularly inbred animal strains). When the
need to control variability is high, as with small effect size, drift
over time can influence experimental outcome independently
of the effect of a controlled variable (e.g., a therapeutic experi-
mental manipulation). This drift can even occur within the time
frame of a single experiment. We are familiar with a case in which
an investigator performed ‘‘complete’’ spinal cord lesions on
a group of animals that received an experimental therapy in the
morning, then performed complete transections on the entire
‘‘control’’ (untreated) group in the afternoon. There was a signifi-
cant difference in functional outcome and axonal ‘‘regenera-
tion’’ between groups. However, independent inspection of the
lesions revealed that all lesions were incomplete in the experi-
mental (morning) group and were more complete in the control
(afternoon) group. Apparently, the investigator, who did not
have much experience in performing spinal cord lesions, gained
greater skill and experience in performing lesions over the oper-
ative day. This highlights the need to intersperse ‘‘control’’ and
‘‘experimental’’ subjects continually, to generally utilize similar
numbers of control and experimental subjects and to perform
studies in a blinded manner.
Methods of Studying Axonal Growth
Themethods used to study axonal growth after spinal cord injury
depend on the axonal system under study and the experimental
hypothesis.
Immunolabeling
For pathways that contain unique proteins, immunolabeling
is often used. For example, 5-hydroxytryptamine (5HT) labeling
is a satisfactory method for identifying serotonergic projections;
dopamine beta hydroxlase (DBH) immunolabeling can identify
cerulospinal projections; and Substance P, IB4, and CGRP
immunolabeling can identify different subclasses of primary
afferents from dorsal root ganglion cells.
Some immunolabels have been used to label specific axonal
systems, but lack specificity leading to potential confounds in
data interpretation. For example, choline acetyltransferase is
expressed by alpha motor neurons and pregangionic sympa-
thetic neurons. Protein kinase C-gamma (PKC-gamma) labeling
has been used to identify CST axons, but this label is not specific
and cannot be used to detect growth responses of CST systems.
PKC-gamma is mainly useful for detecting the loss of axons in
the CST following lesions. Similarly, growth-associated protein
43 (GAP43) labeling has been used by some investigators as
an indicator of growing axons, but in fact, GAP43 is expressed
constitutively by some spinal cord systems including the CST.
Thus the presence of GAP43-labeled axons after a lesion is nota useful indicator of new growth. The study of growth of CST
projections, andmany other systems, requires tracers or genetic
labels.
Tract Tracing
Tract tracing has been the gold standard for studying new
growth from axonal systems that lack specific immunolabels,
including corticospinal, rubrospinal, reticulospinal, and some
sensory systems. Many anterograde tracers are available that
provide exquisite axonal morphology, including dextran amines,
phytohemagglutinin (PHA), and fluorogold. Mini-ruby BDA
provides the additional advantage that its fluorescence can be
directly visualized, without amplification by immunolabeling. A
particularly useful tracer for central sensory projections is the
transganglionic tracer cholera toxin B (CTB). This tracer can be
very simply injected into the sciatic nerve, and it will fill central
dorsal column axonal projections at all levels up to the nucleus
gracilis.
A great benefit of anterograde tracing methods is their system
specificity and degree of anatomical detail. There can be
artifacts, however. For example, tracers that leak into the CSF
can be taken up in unexpected ways after lesions, leading to
misinterpretation of findings (Steward et al., 2007). Anterograde
tracers are typically injected into the site of greatest concentra-
tion of cell bodies projecting axons to the spinal cord, or into
multiple locations. For example, the Tuszynski lab routinely
utilizes 24 injections into the rat motor cortex to label CST axons
projecting to cervical and lumbar spinal cord segments, in an
effort to label as many axons as possible. One consequence,
however, is that because so many axons are labeled, detecting
the origin and course of individual axons around a lesion site is
very difficult. An alternative method is to map the motor cortex
using intracortical microstimulation to label CST projections to
a specific spinal segment, then limit tracer injections to this
identified region.
Retrograde tracingmethods are also useful in studies of spinal
cord injury. Injections of a retrograde tracer like fluorogold into
the intact spinal cord can label essentially all of the neurons
that project to that site. If injected below a complete transection,
a retrograde tracer can label neurons arising from different parts
of the nervous system that may have grown caudal to the lesion.
The relative efficacy of regeneration can be quantified by count-
ing retrogradely labeled cell bodies in spinal segments, brain-
stem, and cortex. An important limitation of retrograde tracing
techniques is that it is not possible to trace regenerating axons.
Also, there can be spread of the tracer through spinal fluid path-
ways or into amatrix placed in the lesion site, leading tomisinter-
pretation of regeneration. Thus, low-volume tracer injections
should be made at a slow rate of infusion, and histological anal-
ysis should include confirmation that tracer has not spread into
the leptomeninges or the lesion site.
Genetic Tracing
Transgenic animals that express fluorescent proteins in specific
neuronal subsets provide potentially powerful tools for the study
of regeneration. One strategy involves expressing fluorescent
proteins under the control of neuron type-specific promoters
(Bareyre et al., 2005). Another approach involves the use of bac-
terial artificial chromosome (BAC) mice (Gong et al., 2003; Hei-
man et al., 2008). Heintz and colleagues developed transgenicNeuron 74, June 7, 2012 ª2012 Elsevier Inc. 787
Figure 9. Genetic Tract Labeling
In vivo gene delivery vectors with dual promoters can identify specific neurons
in vivo that express a candidate regeneration gene of interest and can label the
axonal projections of these neurons exclusively. In this case, AAV2 vectors
expressing a candidate regeneration gene and the copGFP gene have been
injected into the rat motor cortex. The axonal projections of these neurons in
the spinal cord exhibit copGFP labeling (Lo¨w et al., 2010).
(A) Corticospinal axons expressing copGFP are labeled with a light-level
antibody as they approach a C3 dorsal column lesion site; bone marrow
stromal cells have been grafted (g) into the lesion.
(B) In a different field, individual axons that have incorporated the copGFP
reporter are shown with fine morphological detail.
Neuron
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neurons, including corticospinal, raphespinal, and dorsal root
ganglion neurons. Genetic labels can provide specificity in
axonal labeling that is hypothetically independent of tracer trans-
port (Konzack et al., 2007). Moreover, BAC mice bearing GFP-
tagged polyribosomes (BAC-TRAPmice) provide an exceptional
opportunity to identify potential regeneration-associated tran-
scriptional events in a cell-type-specific manner (Heiman et al.,
2008).
Although approaches using genetic labeling offer compelling
promise, there are caveats, in our experience. First, it is essential
to control for the possibility that injury alters the selectivity in the
pattern of expression by particular neuron types (that is, labeling
is no longer completely specific to particular axon types). We
have seen evidence of this after spinal cord injury in mice in
which the CST is genetically labeled. Second, genetic labeling
leads to bilateral labeling, but it is often important to determine
laterality in studies of regeneration. For example, a useful crite-
rion for identifying axons as regenerated is that they extend
along the ‘‘wrong’’ side (Liu et al., 2010; Steward et al., 2008).
Laterality can only be determined when the pathway is labeled
unilaterally. Finally, genetically labeled axons undergoing
Wallerian degeneration continue to be fluorescent for a surpris-
ingly long period of time. This complicates analysis of early
growth responses.
Fluorescent protein-expressing viral vectors have provided
new tools for the study of regeneration (Figure 9). Several sero-
types of AAV vectors nearly exclusively infect neurons, allowing
neuronal infection with fluorescent protein as a tracer that fills the
axons and dendritic trees, providing exquisite anatomical resolu-
tion (Lo¨w et al., 2010). A hypothetical advantage of using GFP as
a neuronal tracer rather than transported dyes is the fact that
GFP reputedly moves through the cell through passive diffusion
rather than axonal transport, and is not accordingly vulnerable to
artifacts associated with injury-related changes in axonal trans-
port. That is, rates of axonal transport increase after neural injury,
and greater tracer labeling in an axon may reflect accelerated788 Neuron 74, June 7, 2012 ª2012 Elsevier Inc.transport rather than true structural change; GFP may not be
subject to this potential artifact.
Viral vectors expressing GFP may also be employed elegantly
to study the effects of genetic manipulation of axonal growth. For
example, we have utilized an AAV vector coding for a candidate
regeneration-associated gene that also expresses the GFP
reporter; a neuron that incorporates the AAV vector will both
express the candidate gene and label that neuron’s axon with
GFP. This allows specific assessment of a gene effect on growth
only in transduced neurons, potentially enhancing the sensitivity
to detect an effect on growth (Lo¨w et al., 2010).
Genetic Animal Models of Regeneration
Transgenic mice can be a very useful model for examining the
role of specific genes in axonal growth after adult injury. Several
points must be considered when interpreting results from these
models, however. First, genes that are deleted in neural develop-
ment may perturb development of spinal pathways, leading to
uncertainties regarding interpretation of results after adult injury.
For example, early post-natal deletion of PTEN enhanced CST
growth after spinal cord injury (Liu et al., 2010); however, deletion
at this stage, while the CST is developing, could have altered the
anatomy of its spinal projections with the result that partial lesion
models in the adult failed to remove aberrant axon projections.
Accordingly, a precise survey of the anatomy of the CST projec-
tion in adult unlesioned PTEN-deletion mice was required to
confirm that axons were not in locations that would be inadver-
tently spared (Liu et al., 2010). Another caveat of transgenic
mouse models in regeneration research is the possibility that
developmental compensation may occur for loss of the targeted
gene, leading to erroneous conclusions regarding the role of the
deleted gene.
Finally, a caveat to studies of axon regeneration in mice is a
unique wound healing response that occurs at the lesion site,
which results in a contracted, cell-rich lesion (Zhang et al.,
1996) rather than a large, cystic lesion cavity. Accordingly, it
remains to be seen whether manipulations that enable axon
growth in mice will also be effective in other species.
The Value of Functional Data
There has been a sense in the spinal cord injury literature that
a finding is not of major importance unless there is a functional
‘‘benefit’’ from a therapeutic manipulation. This perspective is
astonishingly naive. Even among the most impressive reports
of axonal growth to date, the overall restitution of axon number
is far below normal innervation density. Extensive restoration
of function may require restitution of neural circuitry to pre-lesion
patterns that, during development, formed as a result of a precise
orchestration of genetic and epigenetic events sequentially over
time. This collective set of developmental events included both
intracellular mechanisms in the neuron and environmental ex-
pression of diffusible guidance cues, extracellular matrix mole-
cules and cell adhesion molecules in precise temporal and
spatial gradients. Moreover, remyelination of every new axon
segment may be required to overcome conduction block. This
set of restorative events is unlikely to occur after adult injury.
Accordingly, the extent to which nondirected or partially directed
growth can be functionally beneficial, as opposed to deleterious
(causing spasticity or cause pain), remains to be determined. We
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be addressed because, finally, there are manipulations that
produce at least some growth past the lesion.
Directed rehabilitation, trophic gradients and other means
may be required to shape the nature of circuit reformation,
but even under these circumstances, will the number, topog-
raphy, and remyelination of newly growing axons be sufficient
to improve function? Moreover, we must also ask whether
our most commonly used functional measures are relevant to
humans. For example, is restoration of walking ability in a
quadrupedal rodent relevant to the bipedal locomotion of
humans that requires fine control of posture and balance?
Nonetheless, partial improvements in behavior (often optimis-
tically referred to as ‘‘functional recovery’’ in the literature) can be
meaningful and informative regarding cellular and systems-level
mechanisms that are required to improve function. Screening
tools such as the Basso-Beattie-Bresnahan (BBB) scale (Basso
et al., 1995) provide a convenient starting point, but quantifiable
ordinate measures that are directly related to particular axon
systems are needed to definitively relate axon growth with
recovery.
The requirement that experiments pass the criterion of
demonstrating ‘‘functional benefit’’ to be considered of major
importance in the spinal cord injury field should be soundly
rejected by investigators, reviewers, and journal editors. We
remain at a stage of spinal cord injury research in which
discovery of fundamental mechanisms contributing to new
axonal growth is critical: from new mechanistic discoveries
that lead to significant axonal sprouting and regeneration, we
will sequentially amplify the number of growing axons, the
distance over which they grow, and their guidance to and
connection with appropriate targets. Moreover, greater mecha-
nistic understanding of the interaction of growing axons with
motor and sensory activation (electrically or behaviorally, i.e.,
rehabilitation) may then be required to generate functionally
beneficial outcomes. At this point, we simply don’t know what
is reasonable to expect in terms of the functional consequence
of a given degree of regenerative axon growth. Thus, a ‘‘reset’’
of functional expectations is reasonable.
Publishing Discoveries on Axon Regeneration in the
Contemporary Literature
Throughout this primer, we have highlighted the need for rigor
in studies of axon regeneration in the study of spinal cord
injury. Axon regeneration is inherently anatomical, and studies
of regeneration require details of methodology and adequate
presentation of that detail in published works. Yet this compel-
ling need counters modern publishing trends. Today’s most
attractive venues for publishing science frequently do not allow
full presentation of methods or relevant control data, including
full documentation of lesion extent. Indeed, economic pressures
facing journals are leading to presentation of fewer details,
especially in the print version. Moreover, some journals prohibit
supplementary figures, precluding desirable documentation.
A lack of full documentation increases the likelihood that
errors or misinterpretations will go undetected by reviewers
and readers. Failures to replicate published findings continue
to plague the field of spinal cord injury research, especially on
the topic of axon regeneration. It is daunting that every reportof a treatment that produced dramatic regeneration and
recovery of function after spinal cord injury has failed to stand
the test of time and scrutiny. Studies of regeneration after spinal
cord injury require highly compelling data and in depth scrutiny
to avoid leading the field in false directions.
Conclusion
This is a golden era of neuroscience research with significant
potential to impact future human therapy, including spinal cord
injury. We have moved beyond an overly simplistic view of the
organization and function of neural systems, and in parallel
with this, have emerged from an overly simplistic view that we
simply need to ‘‘grow axons’’ to restore function. Further prog-
ress in the field will be enhanced by accurately describing the
biological phenomena we are attempting to understand, and
by usingmodels and interpreting the data they generate in a truly
objective and realistic manner.
ACKNOWLEDGMENTS
The authors are supported by the NIH, the Veterans Administration, the Craig
H. Neilsen Foundation, and the Bernard and Anne Spitzer Charitable Trust.
REFERENCES
Alstermark, B., Pinter, M., and Sasaki, S. (1983). Brainstem relay of disynaptic
pyramidal EPSPs to neck motoneurons in the cat. Brain Res. 259, 147–150.
Alstermark, B., Lundberg, A., and Sasaki, S. (1984). Integration in descending
motor pathways controlling the forelimb in the cat. 12. Interneurones which
may mediate descending feed-forward inhibition and feed-back inhibition
from the forelimb to C3-C4 propriospinal neurones. Exp. Brain Res. 56,
308–322.
Alto, L.T., Havton, L.A., Conner, J.M., Hollis, E.R., 2nd, Blesch, A., and Tuszyn-
ski, M.H. (2009). Chemotropic guidance facilitates axonal regeneration and
synapse formation after spinal cord injury. Nat. Neurosci. 12, 1106–1113.
Anderson, K., Aito, S., Atkins, M., Biering-Sørensen, F., Charlifue, S., Curt, A.,
Ditunno, J., Glass, C., Marino, R., Marshall, R., et al; Functional Recovery
Outcome Measures Work Group. (2008). Functional recovery measures for
spinal cord injury: an evidence-based review for clinical practice and research.
J. Spinal Cord Med. 31, 133–144.
Bareyre, F.M., Kerschensteiner, M., Raineteau, O., Mettenleiter, T.C., Wein-
mann, O., and Schwab, M.E. (2004). The injured spinal cord spontaneously
forms a new intraspinal circuit in adult rats. Nat. Neurosci. 7, 269–277.
Bareyre, F.M., Kerschensteiner, M., Misgeld, T., and Sanes, J.R. (2005). Trans-
genic labeling of the corticospinal tract for monitoring axonal responses to
spinal cord injury. Nat. Med. 11, 1355–1360.
Basso, D.M., Beattie, M.S., andBresnahan, J.C. (1995). A sensitive and reliable
locomotor rating scale for open field testing in rats. J. Neurotrauma 12, 1–21.
Benowitz, L., and Yin, Y. (2008). Rewiring the injured CNS: lessons from the
optic nerve. Exp. Neurol. 209, 389–398.
Benson, M.D., Romero, M.I., Lush, M.E., Lu, Q.R., Henkemeyer, M., and Par-
ada, L.F. (2005). Ephrin-B3 is a myelin-based inhibitor of neurite outgrowth.
Proc. Natl. Acad. Sci. USA 102, 10694–10699.
Bisby, M.A., and Pollock, B. (1983). Increased regeneration rate in peripheral
nerve axons following double lesions: enhancement of the conditioning lesion
phenomenon. J. Neurobiol. 14, 467–472.
Blesch, A., and Tuszynski, M.H. (2009). Spinal cord injury: plasticity, regener-
ation and the challenge of translational drug development. Trends Neurosci.
32, 41–47.
Bonner, J.F., Connors, T.M., Silverman, W.F., Kowalski, D.P., Lemay, M.A.,
and Fischer, I. (2011). Grafted neural progenitors integrate and restoreNeuron 74, June 7, 2012 ª2012 Elsevier Inc. 789
Neuron
Primersynaptic connectivity across the injured spinal cord. J. Neurosci. 31, 4675–
4686.
Bray, G.M., Villegas-Pe´rez, M.P., Vidal-Sanz, M., Carter, D.A., and Aguayo,
A.J. (1991). Neuronal and nonneuronal influences on retinal ganglion cell
survival, axonal regrowth, and connectivity after axotomy. Ann. N Y Acad.
Sci. 633, 214–228.
Cao, Z., Gao, Y., Deng, K., Williams, G., Doherty, P., and Walsh, F.S. (2010).
Receptors for myelin inhibitors: Structures and therapeutic opportunities.
Mol. Cell. Neurosci. 43, 1–14.
Causey, G., and Hoffman, H. (1955). Axon sprouting partially deneurotized
nerves. Brain 78, 661–668.
Coumans, J.V., Lin, T.T., Dai, H.N., MacArthur, L., McAtee, M., Nash, C., and
Bregman, B.S. (2001). Axonal regeneration and functional recovery after
complete spinal cord transection in rats by delayed treatment with transplants
and neurotrophins. J. Neurosci. 21, 9334–9344.
Courtine, G., Song, B., Roy, R.R., Zhong, H., Herrmann, J.E., Ao, Y., Qi, J.,
Edgerton, V.R., and Sofroniew, M.V. (2008). Recovery of supraspinal control
of stepping via indirect propriospinal relay connections after spinal cord injury.
Nat. Med. 14, 69–74.
Courtine, G., Gerasimenko, Y., van den Brand, R., Yew, A., Musienko, P.,
Zhong, H., Song, B., Ao, Y., Ichiyama, R.M., Lavrov, I., et al. (2009). Transfor-
mation of nonfunctional spinal circuits into functional states after the loss of
brain input. Nat. Neurosci. 12, 1333–1342.
Edds, M.V., Jr. (1953). Collateral nerve regeneration. Q. Rev. Biol. 28, 260–276.
Edds, M.V., Jr., and Small, W.T. (1951). The behavior of residual axons in
partially denervated muscles of the monkey. J. Exp. Med. 93, 207–216.
Ertu¨rk, A., Mauch, C.P., Hellal, F., Fo¨rstner, F., Keck, T., Becker, K., Ja¨hrling,
N., Steffens, H., Richter, M., Hu¨bener, M., et al. (2012). Three-dimensional
imaging of the unsectioned adult spinal cord to assess axon regeneration
and glial responses after injury. Nat. Med. 18, 166–171.
Feng, G., Mellor, R.H., Bernstein, M., Keller-Peck, C., Nguyen, Q.T., Wallace,
M., Nerbonne, J.M., Lichtman, J.W., and Sanes, J.R. (2000). Imaging neuronal
subsets in transgenic mice expressing multiple spectral variants of GFP.
Neuron 28, 41–51.
Fitch, M.T., and Silver, J. (2008). Glial Cells, Inflammation and CNS Trauma. In
CNS Regeneration: Basic Science and Clinical Advances, J. Kordower and
M.H. Tuszynski, eds. (San Diego: Elsvier).
Giger, R.J., Hollis, E.R., 2nd, and Tuszynski, M.H. (2010). Guidance molecules
in axon regeneration. Cold Spring Harbor Perspect. Biol. 2, a001867.
Gong, S., Zheng, C., Doughty,M.L., Losos, K., Didkovsky, N., Schambra, U.B.,
Nowak, N.J., Joyner, A., Leblanc, G., Hatten, M.E., and Heintz, N. (2003). A
gene expression atlas of the central nervous system based on bacterial artifi-
cial chromosomes. Nature 425, 917–925.
Griffin, J.W., Pan, B., Polley, M.A., Hoffman, P.N., and Farah, M.H. (2010).
Measuring nerve regeneration in the mouse. Exp. Neurol. 223, 60–71.
Gruner, J.A., Yee, A.K., and Blight, A.R. (1996). Histological and functional
evaluation of experimental spinal cord injury: evidence of a stepwise response
to graded compression. Brain Res. 729, 90–101.
Heiman, M., Schaefer, A., Gong, S., Peterson, J.D., Day, M., Ramsey, K.E.,
Sua´rez-Farin˜as, M., Schwarz, C., Stephan, D.A., Surmeier, D.J., et al. (2008).
A translational profiling approach for the molecular characterization of CNS
cell types. Cell 135, 738–748.
Hoffman, H. (1952). Acceleration and retardation of the process of axon-
sprouting in partially devervated muscles. Aust. J. Exp. Biol. Med. Sci. 30,
541–566.
Jin, Y., Fischer, I., Tessler, A., and Houle, J.D. (2002). Transplants of fibroblasts
genetically modified to express BDNF promote axonal regeneration from
supraspinal neurons following chronic spinal cord injury. Exp. Neurol. 177,
265–275.
Keirstead, S.A., Rasminsky, M., Fukuda, Y., Carter, D.A., Aguayo, A.J., and
Vidal-Sanz, M. (1989). Electrophysiologic responses in hamster superior colli-
culus evoked by regenerating retinal axons. Science 246, 255–257.790 Neuron 74, June 7, 2012 ª2012 Elsevier Inc.Kennedy, D. (2004). The old file-drawer problem. Science 305, 451.
Konzack, S., Thies, E., Marx, A., Mandelkow, E.M., and Mandelkow, E. (2007).
Swimming against the tide: mobility of the microtubule-associated protein tau
in neurons. J. Neurosci. 27, 9916–9927.
Kostyuk, P.G., and Vasilenko, D.A. (1978). Propriospinal neurones as a relay
system for transmission of cortico-spinal influences. J. Physiol. (Paris) 74,
247–250.
Ku¨chler, M., Fouad, K., Weinmann, O., Schwab, M.E., and Raineteau, O.
(2002). Red nucleus projections to distinct motor neuron pools in the rat spinal
cord. J. Comp. Neurol. 448, 349–359.
Kurimoto, T., Yin, Y., Omura, K., Gilbert, H.Y., Kim, D., Cen, L.P., Moko, L.,
Ku¨gler, S., and Benowitz, L.I. (2010). Long-distance axon regeneration in the
mature optic nerve: contributions of oncomodulin, cAMP, and pten gene
deletion. J. Neurosci. 30, 15654–15663.
Liebscher, T., Schnell, L., Schnell, D., Scholl, J., Schneider, R., Gullo, M.,
Fouad, K., Mir, A., Rausch, M., Kindler, D., et al. (2005). Nogo-A antibody
improves regeneration and locomotion of spinal cord-injured rats. Ann. Neurol.
58, 706–719.
Liu, C.N., and Chambers, W.W. (1958). Intraspinal sprouting of dorsal root
axons; development of new collaterals and preterminals following partial
denervation of the spinal cord in the cat. AMA Arch. Neurol. Psychiatry 79,
46–61.
Liu, Y., Kim, D., Himes, B.T., Chow, S.Y., Schallert, T., Murray, M., Tessler, A.,
and Fischer, I. (1999). Transplants of fibroblasts genetically modified to
express BDNF promote regeneration of adult rat rubrospinal axons and
recovery of forelimb function. J. Neurosci. 19, 4370–4387.
Liu, K., Lu, Y., Lee, J.K., Samara, R., Willenberg, R., Sears-Kraxberger, I.,
Tedeschi, A., Park, K.K., Jin, D., Cai, B., et al. (2010). PTEN deletion enhances
the regenerative ability of adult corticospinal neurons. Nat. Neurosci. 13,
1075–1081.
Longo, F.M., Hayman, E.G., Davis, G.E., Ruoslahti, E., Engvall, E., Manthorpe,
M., and Varon, S. (1984). Neurite-promoting factors and extracellular matrix
components accumulating in vivo within nerve regeneration chambers. Brain
Res. 309, 105–117.
Lo¨w, K., Culbertson, M., Bradke, F., Tessier-Lavigne, M., and Tuszynski, M.H.
(2008). Netrin-1 is a novel myelin-associated inhibitor to axon growth.
J. Neurosci. 28, 1099–1108.
Lo¨w, K., Blesch, A., Herrmann, J., and Tuszynski, M.H. (2010). A dual promoter
lentiviral vector for the in vivo evaluation of gene therapeutic approaches to
axon regeneration after spinal cord injury. Gene Ther. 17, 577–591.
Lu, P., Jones, L.L., Snyder, E.Y., and Tuszynski, M.H. (2003). Neural stem cells
constitutively secrete neurotrophic factors and promote extensive host axonal
growth after spinal cord injury. Exp. Neurol. 181, 115–129.
Lu, P., Yang, H., Jones, L.L., Filbin, M.T., and Tuszynski, M.H. (2004). Combi-
natorial therapy with neurotrophins and cAMP promotes axonal regeneration
beyond sites of spinal cord injury. J. Neurosci. 24, 6402–6409.
Lu, P., Blesch, A., Graham, L., Wang, W., Samara, R., Banos, K., Haringer, V.,
Havton, L., Weishaup, N., Bennett, D., et al. (2012). Motor axonal regeneration
after partial and complete spinal cord transection. J. Neurosci., in press.
Ma, C.H., Omura, T., Cobos, E.J., Latre´molie`re, A., Ghasemlou, N., Brenner,
G.J., van Veen, E., Barrett, L., Sawada, T., Gao, F., et al. (2011). Accelerating
axonal growth promotesmotor recovery after peripheral nerve injury inmice. J.
Clin. Invest. 121, 4332–4347.
Maclaren, R.E., and Taylor, J.S. (1997). Regeneration in the developing optic
nerve: correlating observations in the opossum to other mammalian systems.
Prog. Neurobiol. 53, 381–398.
Mantuano, E., Henry, K., Yamauchi, T., Hiramatsu, N., Yamauchi, K., Orita, S.,
Takahashi, K., Lin, J.H., Gonias, S.L., and Campana, W.M. (2011). The
unfolded protein response is a major mechanism by which LRP1 regulates
Schwann cell survival after injury. J. Neurosci. 31, 13376–13385.
McCouch, G.P., Austin, G.M., Liu, C.N., and Liu, C.Y. (1958). Sprouting as
a cause of spasticity. J. Neurophysiol. 21, 205–216.
Neuron
PrimerMcQuarrie, I.G., Grafstein, B., and Gershon, M.D. (1977). Axonal regeneration
in the rat sciatic nerve: effect of a conditioning lesion and of dbcAMP. Brain
Res. 132, 443–453.
Morris, R., Tosolini, A.P., Goldstein, J.D., and Whishaw, I.Q. (2011). Impaired
arpeggio movement in skilled reaching by rubrospinal tract lesions in the rat:
a behavioral/anatomical fractionation. J. Neurotrauma 28, 2439–2451.
Nathan, P.W., and Smith, M.C. (1982). The rubrospinal and central tegmental
tracts in man. Brain 105, 223–269.
Neumann, S., and Woolf, C.J. (1999). Regeneration of dorsal column fibers
into and beyond the lesion site following adult spinal cord injury. Neuron 23,
83–91.
Oudega, M., Varon, S., and Hagg, T. (1994). Regeneration of adult rat sensory
axons into intraspinal nerve grafts: promoting effects of conditioning lesion
and graft predegeneration. Exp. Neurol. 129, 194–206.
Park, K.K., Liu, K., Hu, Y., Smith, P.D., Wang, C., Cai, B., Xu, B., Connolly, L.,
Kramvis, I., Sahin, M., and He, Z. (2008). Promoting axon regeneration in the
adult CNS by modulation of the PTEN/mTOR pathway. Science 322, 963–966.
Raisman, G. (1969). Neuronal plasticity in the septal nuclei of the adult rat.
Brain Res. 14, 25–48.
Ramon y Cajal, S. (1928). Degeneration and Regeneration of the Nervous
System (London: Oxford University Press).
Rosenzweig, E.S., Brock, J.H., Culbertson, M.D., Lu, P., Moseanko, R.,
Edgerton, V.R., Havton, L.A., and Tuszynski, M.H. (2009). Extensive spinal
decussation and bilateral termination of cervical corticospinal projections in
rhesus monkeys. J. Comp. Neurol. 513, 151–163.
Rosenzweig, E.S., Courtine, G., Jindrich, D.L., Brock, J.H., Ferguson, A.R.,
Strand, S.C., Nout, Y.S., Roy, R.R., Miller, D.M., Beattie, M.S., et al. (2010).
Extensive spontaneous plasticity of corticospinal projections after primate
spinal cord injury. Nat. Neurosci. 13, 1505–1510.
Rossignol, S., and Dubuc, R. (1994). Spinal pattern generation. Curr. Opin.
Neurobiol. 4, 894–902.
Schwab, J.M., Brechtel, K., Mueller, C.A., Failli, V., Kaps, H.P., Tuli, S.K., and
Schluesener, H.J. (2006). Experimental strategies to promote spinal cord
regeneration—an integrative perspective. Prog. Neurobiol. 78, 91–116.
Scott, S., Kranz, J.E., Cole, J., Lincecum, J.M., Thompson, K., Kelly, N.,
Bostrom, A., Theodoss, J., Al-Nakhala, B.M., Vieira, F.G., et al. (2008). Design,
power, and interpretation of studies in the standard murine model of ALS.
Amyotroph. Lateral Scler. 9, 4–15.
Shapovalov, A.I., and Gurevitch, N.R. (1970). Monosynaptic and disynaptic
reticulospinal actions on lumbar motoneurons of the rat. Brain Res. 21,
249–263.
Sharp, K.G., Flanagan, L.A., Yee, K.M., and Steward, O. (2012). A re-assess-
ment of a combinatorial treatment involving Schwann cell transplants and
elevation of cyclic AMP on recovery of motor function following thoracic spinal
cord injury in rats. Exp. Neurol. 233, 625–644. Published online December 30,
2010. 10.1016/j.expneurol.2010.12.020.
Steward, O., Zheng, B., and Tessier-Lavigne, M. (2003). False resurrections:
distinguishing regenerated from spared axons in the injured central nervous
system. J. Comp. Neurol. 459, 1–8.Steward, O., Zheng, B., Banos, K., and Yee, K.M. (2007). Response to: Kim
et al., ‘‘axon regeneration in young adult mice lacking Nogo-A/B.’’ Neuron
38, 187-199. Neuron 54, 191–195.
Steward, O., Zheng, B., Tessier-Lavigne, M., Hofstadter, M., Sharp, K., and
Yee, K.M. (2008). Regenerative growth of corticospinal tract axons via the
ventral column after spinal cord injury in mice. J. Neurosci. 28, 6836–6847.
Steward, O., Popovich, P.G., Dietrich, W.D., and Kleitman, N. (2012).
Replication and reproducibility in spinal cord injury research. Exp. Neurol.
233, 597–605. Published online November 10, 2011. 10.1016/j.expneurol.
2011.06.017.
Taylor, L., Jones, L., Tuszynski, M.H., and Blesch, A. (2006). Neurotrophin-3
gradients established by lentiviral gene delivery promote short-distance
axonal bridging beyond cellular grafts in the injured spinal cord. J. Neurosci.
26, 9713–9721.
ten Donkelaar, H.J. (1988). Evolution of the red nucleus and rubrospinal tract.
Behav. Brain Res. 28, 9–20.
ten Donkelaar, H.J., Kusuma, A., and de Boer-Van Huizen, R. (1980). Cells of
origin of pathways descending to the spinal cord in some quadrupedal reptiles.
J. Comp. Neurol. 192, 827–851.
Thompson, C.K., Jayaraman, A., Kinnaird, C., and Hornby, T.G. (2011).
Methods to quantify pharmacologically induced alterations in motor function
in human incomplete SCI. J. Vis. Exp. 50, 1–15.
Tuszynski, M.H., Peterson, D.A., Ray, J., Baird, A., Nakahara, Y., and Gage,
F.H. (1994). Fibroblasts genetically modified to produce nerve growth factor
induce robust neuritic ingrowth after grafting to the spinal cord. Exp. Neurol.
126, 1–14.
Weidner, N., Ner, A., Salimi, N., and Tuszynski, M.H. (2001). Spontaneous cor-
ticospinal axonal plasticity and functional recovery after adult CNS injury.
Proc. Natl. Acad. Sci. USA 98, 3513–3518.
White, S.R., and Neuman, R.S. (1980). Facilitation of spinal motoneurone
excitability by 5-hydroxytryptamine and noradrenaline. Brain Res. 188,
119–127.
Wilson, V.J., and Yoshida, M. (1968). Vestibulospinal and reticulospinal effects
on hindlimb, forelimb, and neck alpha motoneurons of the cat. Proc. Natl.
Acad. Sci. USA 60, 836–840.
Xu, X.M., Chen, A., Gue´nard, V., Kleitman, N., and Bunge, M.B. (1997).
Bridging Schwann cell transplants promote axonal regeneration from
both the rostral and caudal stumps of transected adult rat spinal cord.
J. Neurocytol. 26, 1–16.
Z’Graggen, W.J., Fouad, K., Raineteau, O., Metz, G.A., Schwab, M.E., and
Kartje, G.L. (2000). Compensatory sprouting and impulse rerouting after unilat-
eral pyramidal tract lesion in neonatal rats. J. Neurosci. 20, 6561–6569.
Zhang, Z., Fujiki, M., Guth, L., and Steward, O. (1996). Genetic influences on
cellular reactions to spinal cord injury: a wound healing response present in
normal mice is impaired in mice carrying a mutation (WldS) that causes
delayed Wallerian degeneration. J. Comp. Neurol. 371, 485–495.
Zheng, B., Lee, J.K., and Xie, F. (2006). Genetic mouse models for studying
inhibitors of spinal axon regeneration. Trends Neurosci. 29, 640–646.
Zochodne, D.W. (2012). The challenges and beauty of peripheral nerve
regrowth. J. Peripher. Nerv. Syst. 17, 1–18.Neuron 74, June 7, 2012 ª2012 Elsevier Inc. 791
